Combined blood markers correctly detect early pancreatic cancer in human cancer cells
A newly identified biomarker panel could pave the way to earlier detection and better treatment for pancreatic cancer, according to new research from the Perelman School of Medicine at University of Pennsylvania. Currently over 53,000 people in the United States are diagnosed with pancreatic cancer — the fourth leading cause of cancer death — every year. The blood biomarkers, detailed today in Science Translational Medicine, correctly detected pancreatic cancer in blood samples from patients at different stages of their disease.
The majority of pancreatic cancer patients are not diagnosed until an advanced stage, beyond the point at which their tumors can be surgically removed.
A team led by Ken Zaret, PhD, director of the Penn Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology, and Gloria Petersen, PhD, from the Mayo Clinic, identified a pair of biomarkers that physicians could soon use to discover the disease earlier.
“Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,” Zaret said. The authors anticipate that health care providers will use the early-detection biomarkers to test for their presence and levels in blood from pancreatic cancer patients and blood drawn from individuals with a high risk of developing pancreatic cancer, including those who have a first-degree relative with pancreatic cancer, are genetically predisposed to the disease, or who had a sudden onset of diabetes after the age of 50.
“Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer. A long standing concern has been that patients with pancreatic cancer are often not diagnosed until it is too late for the best chance at effective treatment,” said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center (ACC) at the University of Pennsylvania. “Having a biomarker test for this disease could dramatically alter the outlook for these patients.”
Novel method for discovering pancreatic cancer biomarkers
Credit: The lab of Ken Zaret, Perelman School of Medicine, University of Pennsylvania
The biomarker panel, enabled by discovery work of first author Jungsun Kim, PhD, a postdoctoral fellow in Zaret’s lab, builds on a first-of-its-kind human-cell model of pancreatic cancer progression the lab described in 2013. They used stem-cell technology to create a cell line from a patient with advanced pancreatic ductal adenocarcinoma. Genetically reprogramming late-stage human cancer cells to a stem-cell state enabled them to force the reprogrammed cells to progress to an early cancerous state, revealing secreted blood biomarkers of early-stage disease along the way.
The best candidate biomarker, plasma thrombospondin-2 (THBS2), was screened against 746 cancer and control plasma samples using an inexpensive, commercially available protein-detection assay. The team found that blood levels of THBS2, combined with levels of a known later-stage biomarker called CA19-9, was reliable at detecting the presence of pancreatic cancer in patients.
The team refined the assay with independent investigations of plasma samples from patients with different stages of cancer, from individuals with benign pancreatic disease, and from healthy controls, all obtained from Petersen, who directs the biospecimen resource program for pancreas research at the Mayo Clinic.
“Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer,” Zaret said. “Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method.” The combination panel also improved the ability to distinguish cases of cancer from pancreatitis. The panel will next be validated in a set of samples from pancreatic cancer patients who provided a research blood sample prior to their diagnosis.
The Latest on: Pancreatic cancer
- Tom Watson's wife, Hilary Watson, dies of pancreatic canceron November 29, 2019 at 4:04 pm
Hilary Watson, wife of eight-time major champion Tom Watson, died on Wednesday after a two-year battle with pancreatic cancer. She was 63. The Watsons originally got Hilary’s diagnosis in October 2017 ...
- Branched-chain amino acids sustain pancreatic cancer growth by regulating lipid metabolismon November 29, 2019 at 2:45 am
However, the precise roles of BCAA metabolism in cancer growth and survival remain largely unclear. Here, we found that BCAA metabolism has an important role in human pancreatic ductal adenocarcinoma ...
- Non-SMC condensin I complex subunit H mediates mature chromosome condensation and DNA damage in pancreatic cancer cellson November 29, 2019 at 2:20 am
However, the mechanisms through which NCAPH affects pancreatic cancer (PC) and its molecular function remain unclear. In this study, we examined the role of NCAPH in PC cells. Our results showed that ...
- Golfer Tom Watson's Wife Hilary Dies at 63 from Pancreatic Canceron November 28, 2019 at 12:57 pm
Hilary Watson, the wife of golfer Tom Watson, has died from pancreatic cancer at the age of 63. Barry Hyde, the agent of the eight-time major winner, confirmed she died on Wednesday, two years after ...
- Advances in Health: New Hope for Pancreatic Cancer Patientson November 28, 2019 at 5:00 am
(WTNH)– The pancreas is an important organ nestled deep in the abdomen that aids in digestion and regulates blood sugar levels. Cancer of the pancreas is an especially frightening form of cancer. Not ...
- Pancreatic cancer survivor says diagnosis doesn't have to be a death sentence, but research is keyon November 28, 2019 at 2:03 am
ATLANTA — It's a rare form of cancer that's been getting a lot of attention lately. This year an estimated 56,000 Americans will be diagnosed with pancreatic cancer. Nearly 46,000 of them will die.
- "Extraordinary responders" could hold clues to helping others with pancreatic canceron November 26, 2019 at 8:44 pm
New York — It's estimated that more than 56,000 Americans will be diagnosed with pancreatic cancer this year and nearly 46,000 will die from it. Supreme Court Justice Ruth Bader Ginsburg and "Jeopardy ...
- Newly developed personalized vaccine system could delay onset of pancreatic canceron November 26, 2019 at 10:44 am
Researchers from Queen Mary University of London and Zhengzhou University have developed a personalized vaccine system that could ultimately delay the onset of pancreatic cancer. The study provides ...
- Researchers take first steps toward a vaccine for pancreatic canceron November 26, 2019 at 6:10 am
Researchers from Queen Mary University of London and Zhengzhou University have developed a personalized vaccine system that could ultimately delay the onset of pancreatic cancer. The study ...
- TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Canceron November 25, 2019 at 4:26 pm
Pancreatic Cancer Expected to be the Second Leading Cause of Cancer-Related Death in the U.S. by 2020 1 TYME’s oral SM-88 represents a new approach designed to selectively disrupt protein ...
via Google News and Bing News